I’ve coated two chapter tales earlier than. Not from the same old angle of what occurred and why; for every, I dug deeper into who might win from the wreckage.
The Magellan Aerospace story led me to Howmet. The IKEA retailer closures pointed me to Goal. This week’s Chapter 11 submitting from Focus Issue maker Synergy CHC Corp. factors me squarely to Reckitt Benckiser (RBGLY).
Synergy CHC filed for chapter on September 4, 2026, within the U.S. Chapter Court docket for the District of Columbia, TheStreet reported.
Costco informed the corporate again in July that it could be discontinuing Focus Issue merchandise after a 16-year relationship. You see that one resolution? It price Synergy roughly 58% of its whole 2025 web income, triggered an $18.9 million debt acceleration from its lender, and made Chapter 11 inevitable.
RBGLY presently trades at $14, down 10.62% year-to-date, in accordance with Yahoo Finance.
How a 58% income focus turns into a deadly single level of failure
The Synergy CHC scenario reveals simply how rapidly retail focus can turn out to be a danger. Focus Issue is a purposeful beverage model with a 25-year legacy, having fun with established distribution within the U.S., Canada, and Mexico, and distribution throughout Walmart, Walgreens, Amazon, and BJ’s.
The corporate’s a mind complement with nutritional vitamins, minerals, and neuro-nutrients. It carries a “#1 Pharmacist Really useful” declare from the 2025-2026 U.S. Pharmacy Instances survey for reminiscence assist. None of that mattered as soon as Costco made its resolution.
Extra Retail:
“Costco accounted for roughly 58% of the Firm’s web income throughout the fiscal 12 months ended December 31, 2025,” the SEC submitting said. “The Firm expects Costco’s resolution to have a cloth hostile impact on the Firm’s enterprise, outcomes of operations, liquidity, and monetary situation.”
Costco didn’t give a public motive for dropping the model. It didn’t must. It is a retailer that strikes merchandise in bulk, and it made its vendor resolution for no matter motive.
The $18.9 million debt acceleration that adopted confirmed Synergy had no monetary cushion to outlive even a brief income disruption of this magnitude.
Why I believe Reckitt’s Neuriva is the apparent beneficiary
Three structural benefits make Reckitt the clearest winner.
-
Neuriva is already in Costco’s system. The Neuriva Mind Complement Unique (50 capsules) presently retails at Costco for $43.99. Reckitt doesn’t must win a vendor slot or navigate Costco’s notoriously demanding provider necessities. It’s already accepted, built-in, and promoting. Scaling quantity inside an present provider relationship is operationally simple.
-
Reckitt’s product portfolio matches neatly into the place Costco desires to go. Costco members are likely to gravitate towards premium wellness merchandise backed by established manufacturers and analysis. Reckitt has been aggressively increasing Neuriva, with merchandise together with Neuriva Plus, Neuriva Extremely, and Neuriva Reminiscence 3D. I see these premium formulations align with Costco’s push towards higher-margin well being options much better than the legacy Focus Issue lineup.
-
The regulatory historical past issues, too. Focus Issue has confronted FTC settlements and shopper class-action lawsuits difficult its efficacy claims. Reckitt builds Neuriva’s advertising round clinically studied components and GMO-free formulations.
